Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

Sumiyuki Nishida, Shigeo Koido, Yutaka Takeda, Sadamu Homma, Hideo Komita, Akitaka Takahara, Satoshi Morita, Toshinori Ito, Soyoko Morimoto, Kazuma Hara, Akihiro Tsuboi, Yoshihiro Oka, Satoru Yanagisawa, Yoichi Toyama, Masahiro Ikegami, Toru Kitagawa, Hidetoshi Eguchi, Hiroshi Wada, Hiroaki Nagano, Jun NakataYoshiki Nakae, Naoki Hosen, Yusuke Oji, Toshio Tanaka, Ichiro Kawase, Atsushi Kumanogoh, Junichi Sakamoto, Yuichiro Doki, Masaki Mori, Toshifumi Ohkusa, Hisao Tajiri, Haruo Sugiyama

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02- restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0% (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29%, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity- positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.

Original languageEnglish
Pages (from-to)105-114
Number of pages10
JournalJournal of Immunotherapy
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 1 2014

Fingerprint

gemcitabine
Wilms' Tumor Genes
Cancer Vaccines
Pancreatic Neoplasms
Peptides
Delayed Hypersensitivity
Cytotoxic T-Lymphocytes
Survival
Therapeutics
Vaccines
Combined Vaccines
Phenotype
Subunit Vaccines
Immunotherapy
Survivors
Survival Rate

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. / Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; Homma, Sadamu; Komita, Hideo; Takahara, Akitaka; Morita, Satoshi; Ito, Toshinori; Morimoto, Soyoko; Hara, Kazuma; Tsuboi, Akihiro; Oka, Yoshihiro; Yanagisawa, Satoru; Toyama, Yoichi; Ikegami, Masahiro; Kitagawa, Toru; Eguchi, Hidetoshi; Wada, Hiroshi; Nagano, Hiroaki; Nakata, Jun; Nakae, Yoshiki; Hosen, Naoki; Oji, Yusuke; Tanaka, Toshio; Kawase, Ichiro; Kumanogoh, Atsushi; Sakamoto, Junichi; Doki, Yuichiro; Mori, Masaki; Ohkusa, Toshifumi; Tajiri, Hisao; Sugiyama, Haruo.

In: Journal of Immunotherapy, Vol. 37, No. 2, 01.02.2014, p. 105-114.

Research output: Contribution to journalArticle

Nishida, S, Koido, S, Takeda, Y, Homma, S, Komita, H, Takahara, A, Morita, S, Ito, T, Morimoto, S, Hara, K, Tsuboi, A, Oka, Y, Yanagisawa, S, Toyama, Y, Ikegami, M, Kitagawa, T, Eguchi, H, Wada, H, Nagano, H, Nakata, J, Nakae, Y, Hosen, N, Oji, Y, Tanaka, T, Kawase, I, Kumanogoh, A, Sakamoto, J, Doki, Y, Mori, M, Ohkusa, T, Tajiri, H & Sugiyama, H 2014, 'Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer', Journal of Immunotherapy, vol. 37, no. 2, pp. 105-114. https://doi.org/10.1097/CJI.0000000000000020
Nishida, Sumiyuki ; Koido, Shigeo ; Takeda, Yutaka ; Homma, Sadamu ; Komita, Hideo ; Takahara, Akitaka ; Morita, Satoshi ; Ito, Toshinori ; Morimoto, Soyoko ; Hara, Kazuma ; Tsuboi, Akihiro ; Oka, Yoshihiro ; Yanagisawa, Satoru ; Toyama, Yoichi ; Ikegami, Masahiro ; Kitagawa, Toru ; Eguchi, Hidetoshi ; Wada, Hiroshi ; Nagano, Hiroaki ; Nakata, Jun ; Nakae, Yoshiki ; Hosen, Naoki ; Oji, Yusuke ; Tanaka, Toshio ; Kawase, Ichiro ; Kumanogoh, Atsushi ; Sakamoto, Junichi ; Doki, Yuichiro ; Mori, Masaki ; Ohkusa, Toshifumi ; Tajiri, Hisao ; Sugiyama, Haruo. / Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. In: Journal of Immunotherapy. 2014 ; Vol. 37, No. 2. pp. 105-114.
@article{753563596e2342869bff1aab35c6b8d1,
title = "Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer",
abstract = "Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02- restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0{\%} (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29{\%}, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity- positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.",
author = "Sumiyuki Nishida and Shigeo Koido and Yutaka Takeda and Sadamu Homma and Hideo Komita and Akitaka Takahara and Satoshi Morita and Toshinori Ito and Soyoko Morimoto and Kazuma Hara and Akihiro Tsuboi and Yoshihiro Oka and Satoru Yanagisawa and Yoichi Toyama and Masahiro Ikegami and Toru Kitagawa and Hidetoshi Eguchi and Hiroshi Wada and Hiroaki Nagano and Jun Nakata and Yoshiki Nakae and Naoki Hosen and Yusuke Oji and Toshio Tanaka and Ichiro Kawase and Atsushi Kumanogoh and Junichi Sakamoto and Yuichiro Doki and Masaki Mori and Toshifumi Ohkusa and Hisao Tajiri and Haruo Sugiyama",
year = "2014",
month = "2",
day = "1",
doi = "10.1097/CJI.0000000000000020",
language = "English",
volume = "37",
pages = "105--114",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

AU - Nishida, Sumiyuki

AU - Koido, Shigeo

AU - Takeda, Yutaka

AU - Homma, Sadamu

AU - Komita, Hideo

AU - Takahara, Akitaka

AU - Morita, Satoshi

AU - Ito, Toshinori

AU - Morimoto, Soyoko

AU - Hara, Kazuma

AU - Tsuboi, Akihiro

AU - Oka, Yoshihiro

AU - Yanagisawa, Satoru

AU - Toyama, Yoichi

AU - Ikegami, Masahiro

AU - Kitagawa, Toru

AU - Eguchi, Hidetoshi

AU - Wada, Hiroshi

AU - Nagano, Hiroaki

AU - Nakata, Jun

AU - Nakae, Yoshiki

AU - Hosen, Naoki

AU - Oji, Yusuke

AU - Tanaka, Toshio

AU - Kawase, Ichiro

AU - Kumanogoh, Atsushi

AU - Sakamoto, Junichi

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Ohkusa, Toshifumi

AU - Tajiri, Hisao

AU - Sugiyama, Haruo

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02- restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0% (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29%, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity- positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.

AB - Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide-based vaccine for patients with advanced pancreatic cancer and to make initial assessments of its clinical efficacy and immunologic response. Thirty-two HLA-A*24:02 patients with advanced pancreatic cancer were enrolled. Patients received HLA-A*24:02- restricted, modified 9-mer WT1 peptide (3 mg/body) emulsified with Montanide ISA51 adjuvant (WT1 vaccine) intradermally biweekly and gemcitabine (1000 mg/m) on days 1, 8, and 15 of a 28-day cycle. This combination therapy was well tolerated. The frequencies of grade 3-4 adverse events for this combination therapy were similar to those for gemcitabine alone. Objective response rate was 20.0% (6/30 evaluable patients). Median survival time and 1-year survival rate were 8.1 months and 29%, respectively. The association between longer survival and positive delayed-type hypersensitivity to WT1 peptide was statistically significant, and longer survivors featured a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes both before and after treatment. WT1 vaccine in combination with gemcitabine was well tolerated for patients with advanced pancreatic cancer. Delayed-type hypersensitivity- positivity to WT1 peptide and a higher frequency of memory-phenotype WT1-specific cytotoxic T lymphocytes could be useful prognostic markers for survival in the combination therapy with gemcitabine and WT1 vaccine. Further clinical investigation is warranted to determine the effectiveness of this combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84894412309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894412309&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000020

DO - 10.1097/CJI.0000000000000020

M3 - Article

C2 - 24509173

AN - SCOPUS:84894412309

VL - 37

SP - 105

EP - 114

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -